Century Therapeutics, Inc.
IPSC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -1.09 | -0.07 | -0.12 |
| FCF Yield | -138.84% | -51.84% | -5.59% | -15.36% |
| EV / EBITDA | -0.67 | -1.63 | -2.19 | -9.33 |
| Quality | ||||
| ROIC | -61.37% | -43.15% | -28.88% | -22.42% |
| Gross Margin | 100.00% | 100.00% | -93.71% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.65 | -0.11 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.22% | – | – | – |
| Free Cash Flow Growth | -8.04% | -516.75% | 87.65% | -162.21% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | -0.01 | 0.29 | 0.37 |
| Interest Coverage | 0.00 | -271.38 | -121.11 | -74.42 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -18.33 |
| Cash Conversion Cycle | 84.20 | 108.60 | -142.91 | -625.01 |